Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fritz Offner

Showing results (51-60 of 126) with videos related to

Pageof 13
Sort By:
Leukemia|May 16, 2019
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemiaStephan Stilgenbauer, Thérèse Aurran Schleinitz, Barbara Eichhorst, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin BFritz Offner, Vladimir Krcmery, Marc Boogaerts, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 8, 2003
In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damageKatia Vandenbulcke, Filip De Vos, Fritz Offner, et al.
Blood|August 2, 2015
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCLFritz Offner, Olga Samoilova, Evgenii Osmanov, et al.
Insights Into Imaging|April 10, 2024
Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imagingThomas Van Den Berghe, Bert Verberckmoes, Nicolas Kint, et al.
Haematologica|January 28, 2017
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studyVincent Ribrag, Won Seog Kim, Reda Bouabdallah, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Studies in Health Technology and Informatics|May 25, 2022
Augmenting THerapeutic Effectiveness Through Novel Analytics (ATHENA) - A Public and Private Partnership Project Funded by the Flemish Government (VLAIO)Ploingarm Petsophonsakul, Ashkan Pirmani, Edward De Brouwer, et al.
Clinical Hematology International|October 13, 2022
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) StudyAnn Janssens, Zwi N Berneman, Fritz Offner, et al.
Haematologica|December 10, 2020
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potentialLennart Raman, Malaïka Van der Linden, Ciel De Vriendt, et al.
Pageof 13

Showing results (51-60 of 126) with videos related to

Sort By:
Pageof 13
Leukemia|May 16, 2019
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemiaStephan Stilgenbauer, Thérèse Aurran Schleinitz, Barbara Eichhorst, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin BFritz Offner, Vladimir Krcmery, Marc Boogaerts, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 8, 2003
In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damageKatia Vandenbulcke, Filip De Vos, Fritz Offner, et al.
Blood|August 2, 2015
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCLFritz Offner, Olga Samoilova, Evgenii Osmanov, et al.
Insights Into Imaging|April 10, 2024
Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imagingThomas Van Den Berghe, Bert Verberckmoes, Nicolas Kint, et al.
Haematologica|January 28, 2017
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studyVincent Ribrag, Won Seog Kim, Reda Bouabdallah, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Studies in Health Technology and Informatics|May 25, 2022
Augmenting THerapeutic Effectiveness Through Novel Analytics (ATHENA) - A Public and Private Partnership Project Funded by the Flemish Government (VLAIO)Ploingarm Petsophonsakul, Ashkan Pirmani, Edward De Brouwer, et al.
Clinical Hematology International|October 13, 2022
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) StudyAnn Janssens, Zwi N Berneman, Fritz Offner, et al.
Haematologica|December 10, 2020
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potentialLennart Raman, Malaïka Van der Linden, Ciel De Vriendt, et al.
Pageof 13